7月30日 - ** VYNE Therapeutics VYNE.O股价暴跌 72%，跌至 40 美分的历史最低点
** 如果跌势持续，股价将创下7年多来最糟糕的一天
** 该公司称其治疗白癜风的皮肤病药物Repibresib凝胶未能达到中期试验目标 (link)，即面部白癜风至少改善50%或75%。
** VYNE 将停止正在进行的试验扩展阶段，并寻求外部合作伙伴继续开发 Repibresib。
** 公司称，Repibresib凝胶比安慰剂更容易引起轻微的皮肤副作用和涂抹部位疼痛
** 截至 6 月 30 日，公司拥有约 3960 万美元现金
** 包括本交易日的走势在内，该公司股票今年累计下跌 88
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.